These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 23178471

  • 21. Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction.
    Jiménez C, Chillón Mdel C, Balanzategui A, Puig N, Sebastián E, Alcoceba M, Sarasquete ME, Conde IP, Corral R, Marín LA, Paiva B, Ruano M, Antón A, Maldonado R, San Miguel JF, González M, García-Sanz R.
    Appl Immunohistochem Mol Morphol; 2014; 22(10):768-73. PubMed ID: 24992174
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Frequency of MYD88 L256P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasm.
    Shekhar R, Naseem S, Binota J, Varma N, Malhotra P.
    Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):231-239. PubMed ID: 33217360
    [Abstract] [Full Text] [Related]

  • 27. MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era.
    Nishimura N, Takeuchi K, Asaka R, Tuyama N, Inoue N, Kusano Y, Mishima Y, Yokoyama M, Terui Y.
    Leuk Res; 2020 Oct; 97():106426. PubMed ID: 32781214
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. MYD88 L265P mutation promoted malignant B cell resistance against T cell-mediated cytotoxicity via upregulating the IL-10/STAT3 cascade.
    Qiu H, Gong S, Xu L, Cheng H, Gao L, Chen J, Hu X, Yang J.
    Int Immunopharmacol; 2018 Nov; 64():394-400. PubMed ID: 30253331
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.
    Knittel G, Liedgens P, Korovkina D, Seeger JM, Al-Baldawi Y, Al-Maarri M, Fritz C, Vlantis K, Bezhanova S, Scheel AH, Wolz OO, Reimann M, Möller P, López C, Schlesner M, Lohneis P, Weber AN, Trümper L, German International Cancer Genome Consortium Molecular Mechanisms in Malignant Lymphoma by Sequencing Project Consortium, Staudt LM, Ortmann M, Pasparakis M, Siebert R, Schmitt CA, Klatt AR, Wunderlich FT, Schäfer SC, Persigehl T, Montesinos-Rongen M, Odenthal M, Büttner R, Frenzel LP, Kashkar H, Reinhardt HC.
    Blood; 2016 Jun 02; 127(22):2732-41. PubMed ID: 27048211
    [Abstract] [Full Text] [Related]

  • 34. Transformation to diffuse large B-cell lymphoma with germinal center B-cell like subtype and discordant light chain expression in a patient with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
    Kobayashi H, Asada N, Egusa Y, Ikeda T, Sakamoto M, Abe M, Ennishi D, Sakata M, Takaki A, Kawahara S, Meguri Y, Nishimori H, Fujii N, Matsuoka KI, Sato Y, Yoshino T, Maeda Y.
    Int J Hematol; 2021 Sep 02; 114(3):401-407. PubMed ID: 33907976
    [Abstract] [Full Text] [Related]

  • 35. Allele-specific PCR is a powerful tool for the detection of the MYD88 L265P mutation in diffuse large B cell lymphoma and decalcified bone marrow samples.
    Staiger AM, Ott MM, Parmentier S, Rosenwald A, Ott G, Horn H, Griese EU.
    Br J Haematol; 2015 Oct 02; 171(1):145-8. PubMed ID: 25816840
    [No Abstract] [Full Text] [Related]

  • 36. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
    Zheng M, Perry AM, Bierman P, Loberiza F, Nasr MR, Szwajcer D, Del Bigio MR, Smith LM, Zhang W, Greiner TC.
    Neuropathology; 2017 Dec 02; 37(6):509-516. PubMed ID: 28856744
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825.
    Wang X, Tan Y, Huang Z, Huang N, Gao M, Zhou F, Hu J, Feng W.
    Oncol Rep; 2019 Nov 02; 42(5):1755-1766. PubMed ID: 31432184
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.
    Cao XX, Li J, Cai H, Zhang W, Duan MH, Zhou DB.
    Ann Hematol; 2017 Nov 02; 96(11):1867-1871. PubMed ID: 28803429
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.